prikaz prve stranice dokumenta Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
  Download
PDF 917.3 KB
Scientific paper - Review paper
Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
Biomedicines, 12 (2024), 3; 653. https://doi.org/10.3390/biomedicines12030653
Etrusco, Andrea; Mikuš, Mislav; D’Amato, Antonio; Barra, Fabio; Planinić, Petar; Goluža, Trpimir; Buzzaccarini, Giovanni; Marušić, Jelena; Tešanović, Mara; Laganà, Antonio Simone

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Etrusco, A., Mikuš, M., D’Amato, A., Barra, F., Planinić, P., Goluža, T. ... Laganà, A. S. (2024). Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s. Biomedicines, 12. (3). doi: 10.3390/biomedicines12030653

Etrusco, Andrea, et al. "Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s." Biomedicines, vol. 12, no. 3, 2024. https://doi.org/10.3390/biomedicines12030653

Etrusco, Andrea, Mislav Mikuš, Antonio D’Amato, Fabio Barra, Petar Planinić, Trpimir Goluža, Giovanni Buzzaccarini, Jelena Marušić, Mara Tešanović and Antonio Simone Laganà. "Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s." Biomedicines 12, no. 3 (2024). https://doi.org/10.3390/biomedicines12030653

Etrusco, A., et al. (2024) 'Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s', Biomedicines, 12(3). doi: 10.3390/biomedicines12030653

Etrusco A, Mikuš M, D’Amato A, Barra F, Planinić P, Goluža T, and sur.. Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s. Biomedicines [Internet]. 2024 March 14 [cited 2024 December 25];12(3). doi: 10.3390/biomedicines12030653

A. Etrusco, et al., "Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s", Biomedicines, vol. 12, no. 3, March 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:302957. [Accessed: 25 December 2024]

Metadata
Title (english)Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
AuthorAndrea Etrusco
AuthorMislav Mikuš
AuthorAntonio D’Amato
AuthorFabio Barra
AuthorPetar Planinić
AuthorTrpimir Goluža
AuthorGiovanni Buzzaccarini
AuthorJelena Marušić
AuthorMara Tešanović
AuthorAntonio Simone Laganà
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Gynecology and Obstetrics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Gynecology and Obstetrics
Abstract (english)
Background: The purpose of this narrative review is to describe the mechanisms that are responsible for the development of infertility and PCOS, with a focus on the role of obesity, insulin sensitivity and treatment with metformin and GLP-1s. Methods: The relevant publications were identified after systematic queries of the following sources: PubMed, Google Scholar, Web of Science, and publishers’ databases, complemented by a cross-check of the reference lists. We used a combination of the search terms “polycystic ovary syndrome”, “obesity” and “insulin resistance” with “metformin”, “exenatide”, “liraglutide”, “semaglutide”, “orlistat” and terms relevant to the topic of each paragraph (e.g., “pathophysiology”, “metabolism”, “infertility”, “treatment”). Results: All articles describing the mechanisms responsible for the development of infertility and PCOS, with a focus on the role of obesity, insulin sensitivity and treatment with metformin and GLP-1s, were considered for this review. Conclusions: The existing research on GLP-1 receptor agonists (GLP-1RAs) has not conclusively established a specific therapeutic use for these drugs. Additionally, the efficacy of the newer generation of GLP-1RAs, particularly in terms of dosage and duration of exposure, warrants more extensive research. Understanding the optimal dosing and treatment duration could significantly enhance the therapeutic use of GLP-1RAs in managing PCOS and its associated conditions.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBiomedicines
Numberingvol. 12, no. 3, 653
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines12030653
URN:NBNurn:nbn:hr:105:302957
Publication2024-03-14
Document URLhttps://www.mdpi.com/2227-9059/12/3/653
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-10-22 07:45:00